Clinical Trials Directory

Trials / Completed

CompletedNCT03984370

Dasiglucagon in the Treatment of Postprandial Hypoglycaemia After Roux-en-Y Gastric Bypass

Status
Completed
Phase
Phase 2
Study type
Interventional
Enrollment
10 (actual)
Sponsor
University Hospital, Gentofte, Copenhagen · Academic / Other
Sex
All
Age
18 Years – 75 Years
Healthy volunteers
Accepted

Summary

The aim of this study is investigating the effect of a novel glucagon analogue administration in gastric bypass operated individuals, who are reactive hypoglycemic.

Detailed description

The Roux-En-Y gastric bypass (RYGB) has major health-promoting effects - reversing type-2-diabetes, improving dyslipidemia and inducing robust weight loss. However, several RYGB-individuals, post surgery, suffers from dumping syndrome and postprandial hyperinsulinemic hypoglycemia (PHH) due to the anatomical rearrangement of the gastro-intestinal system. Dasiglugaon (also known as (ZP4207) has shown great pharmacokinetic- and dynamic effects, compared to other glucagon analogues on the market, when administrated to hypoglycemic type-1-diabetics. Therefore we aim to examine the effects of two different doses of dasiglucagon on the postprandial nadir plasma glucose concentration in RYGB-operated individuals suffering from PHH by use of a mixed meal test (MMT). The study is designed as a double-blinded, randomised, 3-period, 3-treatment, crossover study comprising 3 separate treatment days in which participants will undergo an MMT along with one of the following double-blinded interventions: 1. Subcutaneous (sc) placebo (saline) injection 2. Sc injection with 80 μg dasiglucagon 3. Sc injection with 200 μg dasiglucagon

Conditions

Interventions

TypeNameDescription
DRUGZP4207Abdominal SC administration
OTHERPlacebo (saline)Abdominal SC administration

Timeline

Start date
2019-09-18
Primary completion
2020-02-26
Completion
2020-02-26
First posted
2019-06-13
Last updated
2020-03-31

Locations

1 site across 1 country: Denmark

Source: ClinicalTrials.gov record NCT03984370. Inclusion in this directory is not an endorsement.